Nanometer particle target preparation of hydroxycamptothecine, and its preparing method

A hydroxycamptothecin and targeting technology, which is applied in the field of 10-hydroxycamptothecin nanoparticle targeting preparations and its preparation, can solve problems such as drug failure, and achieve improved curative effect, good targeting, and improved curative effect Effect

Inactive Publication Date: 2007-07-25
HUNAN KANGDU PHARMA
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

More than 3.95% of 10-hydroxycamptothecin is combined with serum albumin in the body to form a carboxylate-serum albumin complex, causing more than 95% of the drug to fail
4. Existing 10-hydroxycamptothecin drugs also have adverse reactions such as hematuria, urgency, bone marrow suppression, nausea and vomiting, diarrhea, and rashes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanometer particle target preparation of hydroxycamptothecine, and its preparing method
  • Nanometer particle target preparation of hydroxycamptothecine, and its preparing method
  • Nanometer particle target preparation of hydroxycamptothecine, and its preparing method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The formula that present embodiment adopts is as follows:

[0029] Gelatin 1.8g;

[0030] 10-Hydroxycamptothecin 1.7g;

[0031] 255ml of tert-butanol;

[0032] Vitamin C 40g;

[0033] Chitosan 0.30g;

[0034] Sodium carboxymethyl cellulose 6.50g;

[0035] Water for injection 765ml.

[0036] The preparation method is as described above.

[0037] Pharmacodynamic experiment verification is as follows:

[0038] Mice models of gastric cancer and head and neck cancer were selected and randomly divided into 20 mice in each group.

[0039] Drug treatment group of the present invention is set as:

[0040] Drug group a of the present invention: 10-hydroxycamptothecin gelatin nanoparticles, the dosage is 1.5 mg / kg, twice a day, intraperitoneal injection, for 21 days.

[0041] Drug group b of the present invention: 10-hydroxycamptothecin gelatin nanoparticles, the dosage is 1.0 mg / kg, twice a day, intraperitoneal injection, medication for 21 days.

[0042] Drug group c of...

Embodiment 2

[0050] The formula that present embodiment adopts is as follows:

[0051] Human serum albumin 4.0g;

[0052] 10-Hydroxycamptothecin 3.2g;

[0053] 520ml tert-butanol;

[0054] Vitamin C 82g;

[0055] Chitosan 0.66g;

[0056] Sodium carboxymethyl cellulose 16g;

[0057] Water for injection 1560ml.

[0058] The preparation method is as described above.

[0059] Pharmacodynamic experiment verification is as follows:

[0060] Mice models of gastric cancer and head and neck cancer were selected and randomly divided into 20 mice in each group.

[0061] Drug treatment group of the present invention is set as:

[0062] Drug group a of the present invention: 10-hydroxycamptothecin human serum albumin nanoparticles, the dosage is 1.5mg / kg, twice a day, intraperitoneal injection, medication for 21 days.

[0063] Drug group b of the present invention: 10-hydroxycamptothecin human serum albumin nanoparticles, the dosage is 1.0 mg / kg, twice a day, intraperitoneal injection, medicat...

Embodiment 3

[0072] The formula that present embodiment adopts is as follows:

[0073] Bovine serum albumin 5.4g;

[0074] 10-Hydroxycamptothecin 4.2g;

[0075] tert-butanol 630ml;

[0076] Vitamin C 120g;

[0077] Chitosan 0.90g;

[0078] Sodium carboxymethyl cellulose 20g;

[0079] Water for injection 1900ml.

[0080] The preparation method is as described above.

[0081] Pharmacodynamic experiment verification is as follows:

[0082] Mice models of gastric cancer and head and neck cancer were selected and randomly divided into 20 mice in each group.

[0083] Drug treatment group of the present invention is set as:

[0084] Drug group a of the present invention: 10-hydroxycamptothecin bovine serum albumin nanoparticles, the dosage is 1.5 mg / kg, twice a day, intraperitoneal injection, medication for 21 days.

[0085] Drug group b of the present invention: 10-hydroxycamptothecin bovine serum albumin nanoparticles, the dosage is 1.0 mg / kg, twice a day, intraperitoneal injection, medi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

A targeting nanoparticle of 10-hydroxy camptothecine for treating tumor is proportionally prepared from gelatin, 10-hydroxy camptothecine, tert-butanol, VC, chitosan, carboxymethyl cellulose sodium, and the water for injection. Its preparing process is also disclosed.

Description

technical field [0001] The invention relates to a nanoparticle targeting preparation of 10-hydroxycamptothecin and a preparation method thereof. Background technique [0002] 10-Hydroxycamptothecin is a natural alkaloid extracted from the fruit of camptothecin, a DNA topoisomerase I inhibitor, which can be used as a specific anti-tumor drug in the DNA synthesis phase, and its clinical indications are for a variety of solid tumors, Gastrointestinal tumors, non-small cell tumors, ovarian tumors, head and neck tumors, liver cancer, etc. Due to its wide anti-cancer spectrum, sufficient sources, especially the outstanding advantages of no cross-sensitivity with other anti-cancer drugs, if the defects of its existing technology are overcome, its market prospect will be better than paclitaxel, which is resource-constrained. [0003] The defects of the prior art of 10-hydroxycamptothecin are mainly manifested in: 1. Poor water solubility and low bioavailability. [0004] 2. The pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/475A61K47/42A61P35/00
Inventor 蔡海德
Owner HUNAN KANGDU PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap